MX2019013621A - Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados. - Google Patents

Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.

Info

Publication number
MX2019013621A
MX2019013621A MX2019013621A MX2019013621A MX2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A MX 2019013621 A MX2019013621 A MX 2019013621A
Authority
MX
Mexico
Prior art keywords
methods
long
receptor agonists
immunotherapeutic compositions
acting interleukin
Prior art date
Application number
MX2019013621A
Other languages
English (en)
Inventor
Zhang Ping
Benedict Kirk Peter
Kuo Brewer Peiwen
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2019013621A publication Critical patent/MX2019013621A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente divulgación proporciona un agonista del receptor de IL-15 de acción prolongada, composiciones relacionadas y métodos de preparación y uso, por ejemplo, en el tratamiento de afecciones que responden a la terapia efectiva para proporcionar, por ejemplo, actividad inmuno-sostenida y actividad antitumoral.
MX2019013621A 2017-05-15 2018-05-15 Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados. MX2019013621A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762506494P 2017-05-15 2017-05-15
US201762536966P 2017-07-25 2017-07-25
US201762582186P 2017-11-06 2017-11-06
US201862648240P 2018-03-26 2018-03-26
PCT/US2018/032817 WO2018213341A1 (en) 2017-05-15 2018-05-15 Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods

Publications (1)

Publication Number Publication Date
MX2019013621A true MX2019013621A (es) 2020-01-13

Family

ID=64274790

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013621A MX2019013621A (es) 2017-05-15 2018-05-15 Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.

Country Status (9)

Country Link
US (1) US20200078467A1 (es)
EP (1) EP3624827A4 (es)
JP (2) JP7316222B2 (es)
KR (1) KR20200003922A (es)
CN (1) CN111093688A (es)
AU (2) AU2018270926C1 (es)
CA (1) CA3060410A1 (es)
MX (1) MX2019013621A (es)
WO (1) WO2018213341A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3100007A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
JP2021523741A (ja) 2018-05-14 2021-09-09 ウェアウルフ セラピューティクス， インコーポレイテッド 活性化可能なインターロイキン１２ポリペプチド及びその使用方法
CA3119049A1 (en) * 2018-11-09 2020-05-14 Nektar Therapeutics Long-acting interleukin-15 receptor agonist in combination with another pharmacologically active agent
WO2020206395A1 (en) * 2019-04-05 2020-10-08 Nektar Therapeutics Method for enhancing cellular immunotherapy
SG11202112541RA (en) 2019-05-14 2021-12-30 Werewolf Therapeutics Inc Separation moieties and methods and use thereof
MX2021014189A (es) 2019-05-20 2022-01-06 Cytune Pharma Regimenes de dosificacion de agonistas de la il-2/il-15r?y para el tratamiento del cancer o enfermedades infecciosas.
EP4232068A1 (en) 2020-10-26 2023-08-30 Cytune Pharma IL-2/IL-15RBetaGamma AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
EP4232069A1 (en) 2020-10-26 2023-08-30 Cytune Pharma Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma
KR20240024241A (ko) 2021-06-23 2024-02-23 싸이튠 파마 인터루킨 15 변이체
KR20240043797A (ko) 2021-08-13 2024-04-03 싸이튠 파마 암 치료용 IL-2/IL-15Rβγ 작용제와 항체-약물 접합체 조합

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033240A2 (en) * 2008-09-19 2010-03-25 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
CN102145178B (zh) * 2011-04-15 2012-09-26 北京凯因科技股份有限公司 Peg化白介素15
MA39711A (fr) * 2014-04-03 2015-10-08 Nektar Therapeutics Conjugués d'une fraction d'il-15 et d'un polymère
EP3206713A4 (en) * 2014-10-14 2018-06-27 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
JP7407511B2 (ja) * 2015-10-08 2024-01-04 ネクター セラピューティクス ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用

Also Published As

Publication number Publication date
AU2018270926C1 (en) 2022-10-27
KR20200003922A (ko) 2020-01-10
JP2020519676A (ja) 2020-07-02
AU2018270926B2 (en) 2022-04-07
EP3624827A4 (en) 2021-03-03
CN111093688A (zh) 2020-05-01
AU2022203691A1 (en) 2022-06-16
CA3060410A1 (en) 2018-11-22
JP2023082218A (ja) 2023-06-13
JP7316222B2 (ja) 2023-07-27
WO2018213341A1 (en) 2018-11-22
US20200078467A1 (en) 2020-03-12
AU2018270926A1 (en) 2019-11-07
EP3624827A1 (en) 2020-03-25
AU2022203691B2 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
MX2019013621A (es) Agonistas del receptor de interleuquina-15 de accion prolongada y composiciones y metodos inmunoterapeuticos relacionados.
MX2021005485A (es) Agonista del receptor de interleuquina-15 de accion prolongada con otro agente farmacologicamente activo.
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2019014960A (es) Composiciones de fosfodiesterasa de tipo 5 (pde5) y métodos de inmunoterapia.
AU2017296095B2 (en) Multispecific antibodies against CD40 and CD137
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX2022012082A (es) Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
MX2019009660A (es) Uso de anticuerpos antigeno 4 del linfocito t (ctla-4) con citotoxicidad celular dependiente de anticuerpos (adcc) mejorada para mejorar la respuesta inmune a una vacuna.
PH12015502438B1 (en) Compositions and methods for activating ``stimulator of interferon gene``-dependent signalling
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
SG10201809428UA (en) Insulin receptor partial agonists
TN2017000375A1 (en) Compositions and methods for activating "stimulator of interferon gene" -dependent signalling
MD20170035A2 (ro) Compoziţii şi metode de utilizare pentru tratamentul tulburărilor metabolice
MX2017001406A (es) Agentes a base de flagelina y usos de los mismos, incluyendo vacunación efectiva.
MX2017007585A (es) Anticuerpos anti-c10orf54 y usos de los mismos.
MX2016010854A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de un antagonista de il-4r.
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
PH12016501414B1 (en) Long-acting insulin and use thereof
MX2019010382A (es) Metodo de tratamiento de tumor inmunoterapeutico utilizando un agonista alfa,beta-selectivo del receptor de interleuquina-2 en combinacion con terapia de transferencia celular adoptiva.
MX2018006996A (es) Composiciones y metodos mejorados para la entrega viral de neoepitopos y usos de estos.
NZ735736A (en) Acetate salt of buprenorphine and methods for preparing buprenorphine
WO2021081193A8 (en) Methods of administration of il-2 receptor agonists
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX2020004376A (es) Uso de inhibidores de nox para el tratamiento de cancer.
MX2018004296A (es) Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada.